261149
Lutetium
ingot, 99.9% trace rare earth metals basis
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
Lu
CAS Number:
Molecular Weight:
174.97
UNSPSC Code:
12352300
PubChem Substance ID:
EC Number:
231-103-0
MDL number:
InChI key
OHSVLFRHMCKCQY-UHFFFAOYSA-N
InChI
1S/Lu
SMILES string
[Lu]
assay
99.9% trace rare earth metals basis
form
ingot
reaction suitability
reagent type: catalyst
core: lutetium
resistivity
54 μΩ-cm, 20°C
bp
3402 °C (lit.)
mp
1663 °C (lit.)
density
9.84 g/mL at 25 °C (lit.)
Quality Level
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S Shcherbinin et al.
Physics in medicine and biology, 57(18), 5733-5747 (2012-09-06)
We investigated the quantitative accuracy of SPECT/CT imaging studies as would be performed before and after targeted radionuclide therapy (TRT) using phantom experiments with (i) (99m)Tc, (ii) ¹⁷⁷Lu and (iii) ⁹⁰Y/¹⁷⁷Lu. While the experiment with (99m)Tc imitated a diagnostic scan
Jostein Dahle et al.
Anticancer research, 33(1), 85-95 (2012-12-26)
The monoclonal antibody against CD20, rituximab, alone, or as part of combination therapies, is standard therapy for non-Hodgkin's B-cell lymphoma. Despite significantly better clinical results obtained for beta-emitting radioimmunoconjugates (RICs), RICs targeting CD20 are not commonly used in medical practice
Ksenija R Kumrić et al.
Journal of separation science, 35(18), 2390-2398 (2012-09-22)
In this study, the mass transport resistance in liquid-phase microextraction (LPME) in a single hollow fiber was investigated. A mathematical model has been developed for the determination of the overall mass transfer coefficient based on the acceptor phase in an
Rebecca A Dumont et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 762-769 (2013-03-16)
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer and is an attractive target for radionuclide therapy. In addition, inhibition of the protein kinase mammalian target of rapamycin (mTOR) has been shown to sensitize various cancer cells to the
S M van den Bosch et al.
Nuclear medicine and biology, 40(3), 415-423 (2013-02-06)
We report on our evaluation of the strain-promoted cyclooctyne-azide cycloaddition reaction for use in tumor pretargeting, comprising a side-by-side comparison of probes 1-3 bearing three distinct cyclooctyne moieties based respectively on the 1st and 2nd generation difluorinated cyclooctyne and the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service